Viracta Therapeutics, Inc. (VIRX)
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
$8.85M
Mr. Mark Andrew Rothera
33.00
Cardiff-by-the-Sea, CA
Sep 27, 2005
-0.19
$-1.16
0.94
4.90
0.00%
-0.39
0.51
0.00
4.81
-69.37%
-96.58%
Similar stocks (18)
IGM Biosciences, Inc.
IGMS
Stoke Therapeutics, Inc.
STOK
Terns Pharmaceuticals, Inc.
TERN
EyePoint Pharmaceuticals, Inc.
EYPT
Monte Rosa Therapeutics, Inc.
GLUE
Inozyme Pharma, Inc.
INZY
Biomea Fusion, Inc.
BMEA
Trevi Therapeutics, Inc.
TRVI
Cabaletta Bio, Inc.
CABA
Tenaya Therapeutics, Inc.
TNYA
X4 Pharmaceuticals, Inc.
XFOR
ALX Oncology Holdings Inc.
ALXO
Leap Therapeutics, Inc.
LPTX
Rallybio Corporation
RLYB
Protara Therapeutics, Inc.
TARA
Vincerx Pharma, Inc.
VINC
Lyra Therapeutics, Inc.
LYRA
TRACON Pharmaceuticals, Inc.
TCON
ETF Exposure (10)
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (18)
IGM Biosciences, Inc.
IGMS
Stoke Therapeutics, Inc.
STOK
Terns Pharmaceuticals, Inc.
TERN
EyePoint Pharmaceuticals, Inc.
EYPT
Monte Rosa Therapeutics, Inc.
GLUE
Inozyme Pharma, Inc.
INZY
Biomea Fusion, Inc.
BMEA
Trevi Therapeutics, Inc.
TRVI
Cabaletta Bio, Inc.
CABA
Tenaya Therapeutics, Inc.
TNYA
X4 Pharmaceuticals, Inc.
XFOR
ALX Oncology Holdings Inc.
ALXO
Leap Therapeutics, Inc.
LPTX
Rallybio Corporation
RLYB
Protara Therapeutics, Inc.
TARA
Vincerx Pharma, Inc.
VINC
Lyra Therapeutics, Inc.
LYRA
TRACON Pharmaceuticals, Inc.
TCON
ETF Exposure (10)
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%